P642: A MATCHING-ADJUSTED INDIRECT COMPARISON OF THE EFFICACY AND SAFETY OF ACALABRUTINIB VERSUS ZANUBRUTINIB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Alan Skarbnik,
Adam Kittai,
Miguel Miranda,
Alan Yong,
Jack Roos,
Robert Hettle,
Sarah Palazuelos-Munoz,
Vikram Shetty,
Paolo Ghia
Affiliations
Alan Skarbnik
1 Novant Health Cancer Institute, Lymphoma and CLL program, Charlotte, United States
Adam Kittai
2 The Ohio State University Comprehensive Cancer Center, Division of Hematology, Columbus, United States
Miguel Miranda
3 AstraZeneca, Cambridge, United Kingdom
Alan Yong
4 AstraZeneca, Wilmington, United Kingdom
Jack Roos
5 AstraZeneca, 1800 Concord Pike, Wilmington, United States
Robert Hettle
3 AstraZeneca, Cambridge, United Kingdom
Sarah Palazuelos-Munoz
5 AstraZeneca, 1800 Concord Pike, Wilmington, United States
Vikram Shetty
3 AstraZeneca, Cambridge, United Kingdom
Paolo Ghia
6 5Università Vita-Salute San Raffaele, Milan, Italy